While increasing heart failure treatment intensity reduced risk of death and rehospitalization among hospitalized patients, the use of guideline-recommended dual and triple therapies was low, a study found. ... Almost half (46%) of patients who received
How does that cohort generalize to the millions of elderly, female, and nonwhite [heart failure] patients with comorbid diseases?” Dr. ... In April, the FDA approved another novel drug, ivabradine (Corlanor), to reduce hospitalizations from worsening
therapy to reduce morbidity and mortality in patients with chronic symptomatic heart failure with reduced ejection fraction. ... Head-to-head comparisons of an ARB versus ARNI for heart failure do not exist.
Systolic heart failure is characterized by:. dilated, weak heart and/or thin ventricular wall,. ... Diastolic heart failure is characterized by:. thickened myocardium/hypertrophic ventricle,. low-capacity ventricular chamber,.
Researchers analyzed data from 1,458 heart failure patients in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. ... The results should help physicians adhere to clinical practice guidelines that
A 57-year-old woman is evaluated in the hospital for chronic systolic heart failure. ... The routine treatment of patients with heart failure with warfarin is not indicated.
The industry-funded trial found similar rates of renal failure, hyperkalemia, symptomatic hypotension, and angioedema whether patients started sacubitril-valsartan or enalapril during their heart failure hospitalization. ... lower rate of readmission for
Some differences in heart failure may be due to plausible biological and genetic differences,” summarized Dr. ... Yancy said. This could significantly change thinking about heart failure in African Americans, he explained.
Thirty-day mortality rates may be an effective measure of hospitals' quality of care for heart failure (HF) patients, according to a new study.
The patients had New York Heart Association (NYHA) Class III or IV heart failure. ... The association between VTE risk and heart failure severity was seen in the overall group and the enoxaparin subgroup but not the rivaroxaban subgroup.